Where Are The Novel Products From Big Pharma?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Specialty firms again in 2010 dominated new molecular entity and novel biologic approvals, suggesting that the much-discussed pipeline drought facing big pharma has yet to improve.
You may also be interested in...
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.
2010 Drug Launches: A Year Of Firsts Offers Hope For A Rebound
After several years of either niche or me-too drug launches, 2010 brought an encouraging wave of new molecular entities and novel biologics to market, including several first-in-class drugs addressing large therapeutic areas.